Skip to main content
OpenTrials
Completed

NCT Number: NCT04183842

Evaluation of a Fixed Combination of Herbal Extracts to Prevent Symptoms Alcohol-induced Hangovers

The primary objective of the study is to test whether the tested Product LACIME Anti-hangover is effective in preventing the signs and symptoms of alcohol-induced hangover (such as headache, impaired memory, depression, anxiety, weakness, trouble sleeping and concentrating, nausea, dizziness, sleepiness, thirsty, dry mouth, sweating, sensitivity to light and sounds, vision problems) in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Unimed Medical Center

Abovyan, Yerevan, 0001, Armenia

About this study

LACIME Anti-hangover is a food supplement under the form of a syrup (water/glycerin based) containing plan extracts, each one having choleretic properties.

40 healthy subjects will be tested in a randomized, double-blind, placebo-controlled, crossover trial.

The participants will have to attend the 2 phases of the study during which they will receive in a blind way a product (LACIME Anti-hangover or PLACEBO):

If a participant has received LACIME Anti-hangover for Phase 1, the same participant will receive the PLACEBO for Phase 2 and vice versa.

Inclusion criteria

For inclusion in the study subjects must fulfil all the following criteria:

20-30 years old healthy males and females, Body weight (kg): 60 - 80 in man and 60-70 in women, People who consume alcohol occasionally and who already have to deal with hangovers Healthy volunteers who consume alcohol regularly and moderately, Having given their free, informed and express consent in writing Co-operative, informed of the need and duration of the controls which make it possible to achieve full adherence to the protocol in place.

Exclusion criteria

Excluded from participating in the study:

Volunteers consuming larger amounts of alcohol (more than 2 glasses of alcohol per day) Volunteers taking medication or food supplements that may affect alcohol metabolism.

Women who are pregnant or breastfeeding or plan to become pregnant during the study Subjects with illnesses which may conflict with the investigator's interpretation, if the subject participated in the study Subject planning to change his/her lifestyle during the study (diet, physical activity, etc.) Smoker Subject participating in another study during the clinical study period.

  • At the first medical visit all volunteers will be checked for illegibility, randomized, and sign written informed consent including an obligation that they will not take alcohol within the next week and come to the study site a week later at least 3 hours after the last meal.
  • At the second visit, participants will attend the study site, where each will fill Hangover Severity Symptoms (HSS) form, donate blood and urine for initial analysis.

Then participants take the Product LACIME Anti-hangover or PLACEBO and after 1hour will start to consume alcohol during two hours with meal (3 sandwiches with cheese or ham) on each of the 2 study phases.

Drink consumption, the composition and sequence:

300 ml of Brandy (41% vol. alcohol) corresponding to an intake of 123 ml or 99 g of alcohol 300 ml of Champagne (13% vol. alcohol) corresponding to an intake of 40 ml or 32 g of alcohol This will ensure a 100% hangover syndrome and a total intake of 131 g of alcohol (a dose of approximately 2 g / kg).

Such a dose will provide a peak concentration after 1 hour and should allow to determine the alcohol 15 hours after absorption.

Smaller doses are usually not detectable after 10-12 hours. (Jones, 2008).

D2 test, blood sampling and urine sampling under medical control is achieved before alcohol intake.

D2 test, blood sampling and urine sampling under medical control is achieved 1h, 4h and 15h after alcohol consumption.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 20-30 years old healthy males,
  • Body weight (kg): 60 kg - 80 kg in man,
  • People who consume alcohol occasionally,
  • People who already had to deal with hangovers,
  • Healthy volunteers who consume alcohol regularly and moderately,
  • Having given their free, informed and express consent in writing,
  • Co-operative, informed of the need and duration of the controls which make it possible to achieve full adherence to the protocol in place.

Exclusion criteria

  • Volunteers consuming larger amounts of alcohol (more than 2 glasses of alcohol per day)
  • Volunteers taking medication or food supplements that may affect alcohol metabolism,
  • Subjects with illnesses which may conflict with the investigator's interpretation, if the subject participated in the study,
  • Subject planning to change his lifestyle during the study (diet, physical activity, etc.)
  • Subject participating in another study during the clinical study period.

Treatment and study plan

LACIME Anti-hangover

Dietary Supplement

LACIME Anti-hangover contains the following excipients:

  • Purified water,
  • Xanthan gum,
  • Glycerin,
  • Potassium sorbate (as a preservative)
  • Citric acid (acidity regulator)
  • Aroma (flavouring agent)

LACIME Anti-hangover contains the following plant extracts and vitamin:

  • Curcuma longa rhizome extract (Curcuma),
  • Panax quinquefolius extract (Ginseng panax),
  • Malpighia punicifolia extract (Acerola),
  • Silybum marianum extract (Milk thistle),
  • Desmodium adscendens extract (Desmodium),
  • Pyridoxine chlorhydrate (Vitamin B6).

Placebo

Other

Placebo contains the following excipients :

  • Purified water,
  • Xanthan gum,
  • Glycerin,
  • Potassium sorbate (as a preservative)
  • Citric acid (acidity regulator)
  • Aroma (flavouring agent)

Placebo contains :

  • Carrot juice

Primary outcomes

  1. Evaluation of the difference in Hangover Severity Scores between the activity of LACIME Anti-hangover and the activity of PLACEBO.

    Time frame: Total duration 2 days (Total=16h00: From 1h00 before alcohol intake until 15h after alcohol consumption)

    Evaluation of the difference in Hangover Severity Scores between the activity of LACIME Anti-hangover and the activity of PLACEBO.

    The measure is the true change in self assessment scores from their baseline. 12 self assessed parameters :

    • Headache,
    • Fatigue, weakness
    • Thirsty
    • Dry mouth
    • Nausea
    • Vomiting
    • Trembling
    • Sweat
    • Depressed
    • Anxiety
    • Trouble Sleeping
    • Sensitivity to light

    For each of the above symptoms, the Hangover Severity Scale ranges from 0 to 4.

    The Scores are evaluated according to the following:

    • Absent=0
    • Mild=1
    • Moderate=2
    • Severe=3
    • Incapacitating=4

    Self assessment is achieved:

    • Day 1 : 1h00 before alcohol intake (baseline)
    • Day 1 : Alcohol and meal intake
    • Day 1 : 1h00 after alcohol intake (Visit 1a)
    • Day 1 : 4h00 after alcohol intake (Visit 1b)
    • Day 1 : 15h00 after alcohol intake (Visit 1c)

Secondary outcomes

  1. Evaluation of the difference in Cognitive Performance Score between the activity of LACIME Anti-hangover and the activity of PLACEBO according to "d2" psychometric test.

    Time frame: Total duration 2 days (Total=16h00: From 1h00 before alcohol intake until 15h after alcohol consumption)

    The test "d2" consists of identifying and marking the letters "d" accompanied by two dashes only in the middle of other annoying characters.

    The test "d2" is an array containing 14 lines of 47 characters which must all be checked.

    The recorded figures are :

    • correctly identifyed characters,
    • omissions,
    • confusions,
    • total number of errors.

    Three indices, reveal the evolution of the concentration:

    • Concentration Performance (error-corrected processing rate)
    • Speed of treatment
    • Fluctuation Rate (precision in treatment and accuracy)

    Changes of psychometric parameters are evaluated by d2 test at:

    • Day 1 : 1h00 before alcohol intake (baseline)
    • Day 1 : Alcohol and meal intake
    • Day 1 : 1h00 after alcohol intake (Visit 1a)
    • Day 1 : 4h00 after alcohol intake (Visit 1b)
    • Day 1 : 15h00 after alcohol intake (Visit 1c)
  2. Acetaldehyde blood assay (Jones, 2008)

    Time frame: Total duration 2 days (Total=16h00: From 1h00 before alcohol intake until 15h after alcohol consumption)

    Alcohol is mainly metabolized by hepatic oxydation by NADH / NAD+ enzymatic route.

    Ingestion of Alcohol provoques an increase in the ratio NADH / NAD+ which disrupts all the other metabolic pathways in equilibrium with this coenzyme.

    In the first stage of hepatic metabolism, the enzyme dehydrogenase converts alcohol into Acetaldehyde, a very toxic substance that has effects on the entire body.

    Acetaldehyde is a choice marker to evaluate the level of alcoholic intoxication whenever it is an acute, massive or chronic absorption.

    Titration of blood concentration of Acetaldehyde in mg/l

    Changes of blood parameters from baseline are evaluated at:

    • Day 1 : 1h00 before alcohol intake (baseline)
    • Day 1 : Alcohol and meal intake
    • Day 1 : 1h00 after alcohol intake (Visit 1a)
    • Day 1 : 4h00 after alcohol intake (Visit 1b)
    • Day 1 : 15h00 after alcohol intake (Visit 1c)

Sponsors and collaborators

Lead sponsor

Incara Lab

Industry

Collaborators

  • Phytomed AB

Registry information

Official study title

Evaluation of a Fixed Combination of Herbal Extracts to Prevent Symptoms Alcohol-induced Hangovers : A Randomized, Double Blind Placebo Controlled Crossover Study.

Acronym: LACIME

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 3, 2019
Registry last updated
Dec 3, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.